Drugs / GNR-067
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04667039 Comparator | Mar 2022 → Aug 2024 | wet macular degeneration | AO GENERIUM | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GNR-067 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04667039 ↗ |
| Modality | Monoclonal antibody | “GNR-067 (JSC \"GENERIUM\", the Russian Federation) is a humanized recombinant monoclonal antibody” NCT04667039 ↗ |
| Route | Intravitreal | “GNR-067 will be used intravitreally once every 4 weeks” NCT04667039 ↗ |